Por favor, use este identificador para citar o enlazar este ítem:
http://conacyt.repositorioinstitucional.mx/jspui/handle/1000/3476| Ribavirin and Interferon Therapy for Critically Ill Patients With Middle East Respiratory Syndrome: A Multicenter Observational Study. | |
| Arabi Yaseen M. Shalhoub Sarah. Mandourah Yasser. Al-Hameed Fahad. Al-Omari Awad. Al Qasim Eman. Jose Jesna. Alraddadi Basem. Almotairi Abdullah. Al Khatib Kasim. Abdulmomen Ahmed. Qushmaq Ismael. Sindi Anees A. Mady Ahmed. Solaiman Othman. Al-Raddadi Rajaa. Maghrabi Khalid. Ragab Ahmed. Al Mekhlafi Ghaleb A. Balkhy Hanan H. Al Harthy Abdulrahman. Kharaba Ayman. Gramish Jawaher A. Al-Aithan Abdulsalam M. Al-Dawood Abdulaziz. Merson Laura. Hayden Frederick G. Fowler Robert. | |
| Acceso Abierto | |
| Atribución-NoComercial-SinDerivadas | |
| 10.1093/cid/ciz544 | |
| BACKGROUND:The objective of this study was to evaluate the effect of ribavirin and recombinant interferon (RBV/rIFN) therapy on the outcomes of critically ill patients with Middle East respiratory syndrome (MERS), accounting for time-varying confounders. METHODS:This is a retrospective cohort study of critically ill patients with laboratory-confirmed MERS from 14 hospitals in Saudi Arabia diagnosed between September 2012 and January 2018. We evaluated the association of RBV/rIFN with 90-day mortality and MERS coronavirus (MERS-CoV) RNA clearance using marginal structural modeling to account for baseline and time-varying confounders. RESULTS:Of 349 MERS patients, 144 (41.3%) patients received RBV/rIFN (RBV and/or rIFN-α2a, rIFN-α2b, or rIFN-β1a; none received rIFN-β1b). RBV/rIFN was initiated at a median of 2 days (Q1, Q3: 1, 3 days) from intensive care unit admission. Crude 90-day mortality was higher in patients with RBV/rIFN compared to no RBV/rIFN (106/144 [73.6%] vs 126/205 [61.5%]; P = .02]. After adjusting for baseline and time-varying confounders using a marginal structural model, RBV/rIFN was not associated with changes in 90-day mortality (adjusted odds ratio, 1.03 [95% confidence interval {CI}, .73-1.44]; P = .87) or with more rapid MERS-CoV RNA clearance (adjusted hazard ratio, 0.65 [95% CI, .30-1.44]; P = .29). CONCLUSIONS:In this observational study, RBV/rIFN (RBV and/or rIFN-α2a, rIFN-α2b, or rIFN-β1a) therapy was commonly used in critically ill MERS patients but was not associated with reduction in 90-day mortality or in faster MERS-CoV RNA clearance. | |
| Clinical infectious diseases : an official publication of the Infectious Diseases Society of America | |
| 2020 | |
| Artículo | |
| https://academic.oup.com/cid/article-pdf/doi/10.1093/cid/ciz544/31790387/ciz544.pdf | |
| Inglés | |
| VIRUS RESPIRATORIOS | |
| Aparece en las colecciones: | Artículos científicos |
Cargar archivos:
| Fichero | Tamaño | Formato | |
|---|---|---|---|
| 1104303.pdf | 466.95 kB | Adobe PDF | Visualizar/Abrir |